JPRN-UMIN000007944招募中未知
Stop imatinib or dasatinib study in CP-CML patients mainitaining complete molecular response for two years - TWMU-TKI-STOP-Study
Tokyo Women's Medical University0 个研究点目标入组 40 人开始时间: 2012年6月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1 Active primary double cancers 2 Pregnant or breast-feeding women 3 Patients who are not considered apropriate candicdates for this clinical trial by the investigators, because of past history of diseases, co-morbidities, or other reasons.
研究者
相似试验
进行中（未招募）
1 期
Arrest Imatinib or Dasatinib in CML patients with Deep Molecular ResponsesChronic phase CML patients with BCR-ABL/ABLIS transcript levels below MR3 (<0.1%) and aboveMR4.5 (>0.0032%) at the time of accrual.MedDRA version: 20.0Level: LLTClassification code 10009015Term: Chronic myeloid leukemiaSystem Organ Class: 100000004864EUCTR2014-001603-42-ITAIL CATANIA ASSOCIAZIONE ITALIANA CONTRO LEUCEMIE-LINFOMI E MIELOMA ONLUS222
已完成
不适用
Phase II study of dasatinib for CML-CP patients with suboptima/failure after treatment of imatinibJPRN-UMIN000004280Fukuoka CML stem cell research group20
招募中
2 期
Imatinib discontinuation for Chronic Myelogenou Leukemia-Chronic Phase with 2 years complete molecular remission.Chronic Myelogenou Leukemia-Chronic Phase who have maintained complete molecular remission for at least 2 years.JPRN-UMIN000012472Epidemiological and Clinical Research Information Network (ECRIN)100
尚未招募
不适用
To stop the use of Imatinib in CML-CP patientsCTRI/2019/07/020407DR BRA IRCH AIIMS
招募中
2 期
Dasatinib discontinuation for Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission.JPRN-UMIN000008999Epidemiological and Clinical Research Information Network(ECRIN)50